2023 World Conference on Lung Cancer (Posters)-P2.11. SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation

P2.11. SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation - PDF(Abstract)

Back to course

Pdf Summary

The SHERLOCK trial is a Phase II clinical trial aiming to assess the activity and tolerability of sotorasib, a specific KRASG12C inhibitor, in combination with carboplatin-pemetrexed and bevacizumab-biosimilar for the treatment of non-squamous advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation. The trial is a collaboration between the Thoracic Oncology Group of Australasia and the National Health and Medical Research Council Clinical Trials Centre at the University of Sydney. The target population includes adult participants with newly diagnosed or recurrent non-squamous NSCLC with KRASG12C mutation, with good performance status and adequate organ function. The study treatment consists of 4 cycles of induction treatment followed by maintenance treatment until disease progression or unacceptable toxicity. The primary objective of the trial is to assess the objective response rate, with secondary objectives including progression-free survival, duration of response, overall survival, patient reported outcomes, and adverse events. Tumour and blood samples are being collected for additional studies. The trial aims to recruit a total of 52 participants and commenced recruitment in August 2022. The study is ongoing.

Asset Subtitle

Chee Lee

Meta Tag

Speaker Chee Lee

Topic Metastatic NSCLC: Targeted Therapy - KRAS/MET

Keywords

SHERLOCK trial

Phase II clinical trial

sotorasib

KRASG12C inhibitor

non-small cell lung cancer

NSCLC

KRASG12C mutation

objective response rate

progression-free survival

adverse events